Volume 21 Supplement 1

Results from the Phase I study programme for navafenterol (AZD8871), a novel inhaled dual pharmacology bronchodilator (MABA)

Research

The publication costs for this supplement were funded by AstraZeneca. The articles have undergone the journal’s standard peer-review process. The supplement editors declare no competing interests.

Edited by Arnaud Bourdin and Kelan Tantisira

Navafenterol (AZD8871) in patients with mild asthma: a randomised placebo-controlled phase I study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses of this novel inhaled long-acting dual-pharmacology bronchodilator

Navafenterol (AZD8871) is an inhaled long-acting dual-pharmacology muscarinic antagonist/β₂-adrenoceptor agonist (MABA) in development for the treatment of obstructive airways diseases. The safety, tolerability, ...

Authors: Eulalia Jimenez, Carol Astbury, Muna Albayaty, Ulrika Wählby-Hamrén, Beatriz Seoane, Cristina Villarroel, Helena Pujol, Maria Jesus Bermejo, Ajay Aggarwal and Ioannis Psallidas

Citation: Respiratory Research 2020 21(Suppl 1):211

Content type: Research Published on: 9 September 2020
- View Full Text
- View PDF
Navafenterol (AZD8871) in patients with COPD: a randomized, double-blind, phase I study evaluating safety and pharmacodynamics of single doses of this novel, inhaled, long-acting, dual-pharmacology bronchodilator

Navafenterol (AZD8871) is a dual-pharmacology muscarinic antagonist β₂₋agonist (MABA) molecule in development for the treatment of chronic obstructive pulmonary disease (COPD). The pharmacodynamics, safety and to...

Authors: Dave Singh, Victor Balaguer, Carol Astbury, Ulrika Wählby-Hamrén, Eulalia Jimenez, Beatriz Seoane, Cristina Villarroel, Alejhandra Lei, Ajay Aggarwal and Ioannis Psallidas

Citation: Respiratory Research 2020 21(Suppl 1):102

Content type: Research Published on: 9 September 2020
- View Full Text
- View PDF
Navafenterol (AZD8871) in healthy volunteers: safety, tolerability and pharmacokinetics of multiple ascending doses of this novel inhaled, long-acting, dual-pharmacology bronchodilator, in two phase I, randomised, single-blind, placebo-controlled studies

Navafenterol (AZD8871) is a novel, long-acting, dual-pharmacology (muscarinic receptor antagonist and β₂₋adrenoceptor agonist) molecule in development for chronic obstructive pulmonary disease and asthma.

Authors: Victor Balaguer, Muna Albayaty, Eulalia Jimenez, Ulrika Wählby-Hamrén, Carol Astbury, Beatriz Seoane, Marie-Pierre Malice, Alejhandra Lei, Ajay Aggarwal and Ioannis Psallidas

Citation: Respiratory Research 2020 21(Suppl 1):212

Content type: Research Published on: 9 September 2020
- View Full Text
- View PDF

Results from the Phase I study programme for navafenterol (AZD8871), a novel inhaled dual pharmacology bronchodilator (MABA)

Research

Navafenterol (AZD8871) in patients with mild asthma: a randomised placebo-controlled phase I study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses of this novel inhaled long-acting dual-pharmacology bronchodilator

Navafenterol (AZD8871) in patients with COPD: a randomized, double-blind, phase I study evaluating safety and pharmacodynamics of single doses of this novel, inhaled, long-acting, dual-pharmacology bronchodilator

Navafenterol (AZD8871) in healthy volunteers: safety, tolerability and pharmacokinetics of multiple ascending doses of this novel inhaled, long-acting, dual-pharmacology bronchodilator, in two phase I, randomised, single-blind, placebo-controlled studies

Follow

Annual Journal Metrics

Respiratory Research

Contact us